Suppliers and packagers for generic pharmaceutical drug: epinephrine bitartrate; lidocaine hydrochloride

epinephrine bitartrate; lidocaine hydrochloride

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Deproco	LIGNOSPAN FORTE	epinephrine bitartrate; lidocaine hydrochloride	INJECTABLE;INJECTION	088389	ANDA	Septodont, Inc.	0362-0262-05	50 CARTRIDGE in 1 CARTON (0362-0262-05) / 1.7 mL in 1 CARTRIDGE	2018-08-10
Deproco	LIGNOSPAN FORTE	epinephrine bitartrate; lidocaine hydrochloride	INJECTABLE;INJECTION	088389	ANDA	Septodont, Inc.	0362-1096-70	5 BLISTER PACK in 1 CARTON (0362-1096-70) / 10 CARTRIDGE in 1 BLISTER PACK / 1.7 mL in 1 CARTRIDGE	2017-12-01
Deproco	LIGNOSPAN FORTE	epinephrine bitartrate; lidocaine hydrochloride	INJECTABLE;INJECTION	088389	ANDA	Henry Schein Inc.	0404-6500-15	50 CARTRIDGE in 1 CARTON (0404-6500-15) / 1.7 mL in 1 CARTRIDGE	2011-11-07
Deproco	LIGNOSPAN FORTE	epinephrine bitartrate; lidocaine hydrochloride	INJECTABLE;INJECTION	088389	ANDA	Patterson Dental	50227-1020-5	50 CARTRIDGE in 1 CARTON (50227-1020-5) / 1.7 mL in 1 CARTRIDGE	2011-11-07
Deproco	LIGNOSPAN FORTE	epinephrine bitartrate; lidocaine hydrochloride	INJECTABLE;INJECTION	088389	ANDA	Dentsply Pharmaceutical	66312-181-16	50 CARTRIDGE in 1 CARTON (66312-181-16) / 1.7 mL in 1 CARTRIDGE	1985-01-22

Pharmaceutical Suppliers for Epinephrine Bitartrate and Lidocaine Hydrochloride

Last updated: February 19, 2026

This analysis identifies key global suppliers for epinephrine bitartrate and lidocaine hydrochloride, crucial active pharmaceutical ingredients (APIs) for emergency medical and anesthetic applications. The landscape is characterized by a limited number of API manufacturers holding significant market share, with regulatory compliance and consistent quality as primary differentiators.

Who Are the Primary Global Manufacturers of Epinephrine Bitartrate API?

The production of epinephrine bitartrate API is concentrated among a select group of manufacturers meeting stringent global pharmaceutical quality standards. These suppliers are critical for the global supply chain of epinephrine, an essential medicine used to treat anaphylaxis and cardiac arrest.

Key manufacturers include:

• Saneca Pharmaceuticals: A European-based pharmaceutical company with a long-standing history in API manufacturing, including epinephrine. They operate from a facility in Slovakia and are a significant supplier to global markets. Saneca holds a substantial share of the epinephrine bitartrate API market.
• SPS Pharma: Based in India, SPS Pharma is another prominent API manufacturer with epinephrine bitartrate in its portfolio. Indian API manufacturers are recognized for their cost-competitiveness and adherence to international regulatory guidelines.
• Other Potential Suppliers: While specific market share data is proprietary, other manufacturers in regions like China and the United States may also produce epinephrine bitartrate API. However, their global reach and regulatory certifications are key factors in their market penetration.

The production capacity and regulatory approvals (e.g., FDA, EMA) of these suppliers are critical for ensuring a stable supply. Lead times for API orders can range from 3 to 9 months, depending on production schedules and batch sizes.

What Are the Leading Global Suppliers of Lidocaine Hydrochloride API?

Lidocaine hydrochloride is a widely used local anesthetic and antiarrhythmic drug. Its production is more distributed than epinephrine bitartrate, with several manufacturers globally supplying the API. Quality, purity, and regulatory compliance are paramount for these suppliers.

Leading suppliers of lidocaine hydrochloride API include:

• Hubei Biocause Pharmaceutical Co., Ltd.: A major Chinese API producer with a significant global presence. They offer a broad range of APIs, including lidocaine hydrochloride, and adhere to international cGMP standards. Their large-scale production capabilities contribute to competitive pricing.
• Anqiu Pharmaceutical Co., Ltd.: Another prominent Chinese manufacturer of lidocaine hydrochloride. Chinese manufacturers often leverage scale and integrated production processes to supply a substantial portion of the global market.
• Dipharma Francis S.r.l.: An Italian API manufacturer with a strong reputation for high-quality pharmaceutical ingredients. Dipharma has a global distribution network and focuses on complex APIs, including lidocaine hydrochloride.
• Novartis (through its generics division): While a large pharmaceutical conglomerate, Novartis may also be involved in the supply of lidocaine hydrochloride API through its various manufacturing arms or subsidiaries, often catering to internal needs and external markets.
• SPS Pharma: As mentioned for epinephrine, SPS Pharma also produces lidocaine hydrochloride API, further solidifying its position as a multi-product API supplier.

The global supply of lidocaine hydrochloride is influenced by factors such as raw material availability, manufacturing costs, and the volume of generic drug production worldwide.

What Regulatory Standards Must API Suppliers Adhere To?

Suppliers of epinephrine bitartrate and lidocaine hydrochloride must comply with stringent international regulatory standards to ensure the safety, efficacy, and quality of their products. Failure to meet these standards can result in market exclusion and significant financial penalties.

Key regulatory bodies and standards include:

• U.S. Food and Drug Administration (FDA): Manufacturers supplying to the U.S. market must adhere to FDA's Current Good Manufacturing Practices (cGMP). This includes facility inspections, process validation, and rigorous quality control measures. The FDA maintains an Electronic Drug Master File (eDMF) system where API manufacturers submit detailed information about their manufacturing processes and controls.
• European Medicines Agency (EMA): For the European Union market, suppliers must meet EMA's GMP guidelines. This often involves obtaining a Certificate of Suitability to the Monographs of the European Pharmacopoeia (CEP) for APIs, which demonstrates compliance with European Pharmacopoeia standards.
• Other National Regulatory Authorities: Suppliers also need to comply with the requirements of other national regulatory bodies, such as Health Canada, Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and the Australian Therapeutic Goods Administration (TGA).
• Pharmacopoeial Standards: APIs must meet the specifications outlined in major pharmacopoeias, including:
  • United States Pharmacopeia (USP)
  • European Pharmacopoeia (Ph. Eur.)
  • Japanese Pharmacopoeia (JP)
  • British Pharmacopoeia (BP)

API manufacturers typically undergo regular audits by these regulatory agencies and by their pharmaceutical customers. The time to obtain initial regulatory approval or a CEP can range from 12 to 24 months.

What Are the Key Quality Control Parameters for These APIs?

Rigorous quality control is essential for both epinephrine bitartrate and lidocaine hydrochloride to guarantee their suitability for pharmaceutical formulations. These parameters ensure API purity, potency, and absence of harmful impurities.

Critical quality control parameters include:

• Assay (Potency): This measures the concentration of the active ingredient. For epinephrine bitartrate, it is typically expressed as a percentage of the labeled amount, with tight limits (e.g., 97.0% to 102.0% of C13H18NO4·C4H6O6). For lidocaine hydrochloride, the assay is similarly critical (e.g., 98.5% to 101.0% of C14H22N2O·HCl on the dried basis).
• Related Substances/Impurities: These are impurities that may arise from the synthesis process or degradation. Limits are set for specific known impurities and for total impurities, often in the parts per million (ppm) range, as defined by pharmacopoeial monographs. Examples include related compounds like metanephrine for epinephrine and various precursors or degradation products for lidocaine.
• Residual Solvents: Solvents used during the manufacturing process must be controlled within strict limits to ensure patient safety, as defined by ICH Q3C guidelines.
• Heavy Metals: Limits for heavy metals (e.g., lead, mercury) are critical due to their toxicity.
• Water Content/Loss on Drying: This parameter ensures that the API is not overly hydrated or dried, which can affect stability and potency.
• pH: The pH of a solution of the API is a critical indicator of its stability and suitability for formulation.
• Appearance: The physical appearance (color, form) is a basic but important quality check.
• Microbial Limits: For sterile injectable formulations, the API may need to meet stringent microbial limits or be sterilized post-API production.

These quality control tests are performed on each batch of API before release, and the results are documented in a Certificate of Analysis (CoA).

What Are the Commercial and Supply Chain Considerations for These APIs?

The commercial supply chain for epinephrine bitartrate and lidocaine hydrochloride is influenced by manufacturing concentration, regulatory hurdles, and global demand. For pharmaceutical companies, securing reliable and compliant suppliers is a strategic imperative.

Key considerations include:

• Supplier Qualification: Pharmaceutical companies conduct extensive audits and qualification processes for potential API suppliers. This involves assessing manufacturing capabilities, quality management systems, regulatory compliance history, and financial stability.
• Dual Sourcing: To mitigate supply chain risks, particularly for critical medicines like epinephrine, companies often pursue dual sourcing strategies. This involves qualifying at least two suppliers to ensure continuity in case of production disruptions at one facility.
• Contract Manufacturing Agreements (CMAs): Long-term CMAs are common, providing price stability and guaranteed supply volumes. These agreements typically outline quality standards, delivery schedules, and intellectual property rights.
• Geopolitical and Environmental Risks: The concentration of manufacturing in certain regions (e.g., China, India) exposes the supply chain to geopolitical risks, trade disputes, and environmental regulations that can impact production.
• Cost of Goods: While quality and reliability are paramount, the cost of API is a significant factor in the overall cost of finished drug products. Manufacturers seek competitive pricing without compromising on quality.
• Lead Times and Inventory Management: Managing lead times of several months requires careful inventory planning and forecasting to avoid stock-outs.
• Regulatory Intelligence: Staying abreast of evolving regulatory requirements in key markets is crucial for both suppliers and buyers.

The market for these APIs is relatively stable but can experience price volatility due to raw material costs and supply/demand imbalances.

Key Takeaways

• Epinephrine Bitartrate: Supply is concentrated among a few global manufacturers, with Saneca Pharmaceuticals and SPS Pharma being significant players. Regulatory compliance and consistent quality are paramount.
• Lidocaine Hydrochloride: The supply chain for lidocaine hydrochloride is more diversified, with several manufacturers in China (e.g., Hubei Biocause, Anqiu Pharmaceutical) and Europe (e.g., Dipharma).
• Regulatory Scrutiny: Suppliers must adhere to stringent cGMP standards set by regulatory bodies like the FDA and EMA, and meet pharmacopoeial specifications.
• Quality Control: Rigorous testing for assay, impurities, residual solvents, and heavy metals is mandatory for both APIs.
• Supply Chain Strategy: Pharmaceutical companies employ dual sourcing, long-term contracts, and thorough supplier qualification to ensure a secure and compliant supply of these critical APIs.

Frequently Asked Questions

1. How can a pharmaceutical company verify the quality of an epinephrine bitartrate API supplier?

Verification involves comprehensive supplier audits assessing cGMP compliance, reviewing batch records and CoAs, inspecting manufacturing facilities, and conducting independent testing of API samples. A strong regulatory history and valid DMF or CEP are critical prerequisites.

2. What are the primary risks associated with relying on a single supplier for lidocaine hydrochloride API?

Risks include production disruptions due to unforeseen events (e.g., natural disasters, regulatory actions, labor disputes), price increases due to lack of competition, and potential quality deviations that may not be immediately apparent.

3. How do pharmacopoeial standards impact the manufacturing process for these APIs?

Pharmacopoeial monographs (e.g., USP, Ph. Eur.) define the specific tests, analytical procedures, and acceptance criteria that an API must meet. Manufacturers must design their synthesis and purification processes to consistently produce material that conforms to these standards.

4. Can a small pharmaceutical startup easily source epinephrine bitartrate API?

Sourcing APIs, especially for controlled substances or critical drugs like epinephrine, can be challenging for startups. Established suppliers often prefer to work with larger, established pharmaceutical companies due to volume requirements and the extensive qualification process. Startups may need to partner with experienced contract manufacturers or distributors.

5. What is the typical shelf life of epinephrine bitartrate and lidocaine hydrochloride APIs?

The shelf life of an API is determined by stability studies conducted by the manufacturer. For both epinephrine bitartrate and lidocaine hydrochloride, typical shelf lives are often in the range of 2 to 5 years, provided the API is stored under recommended conditions (e.g., protected from light, controlled temperature).

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA Website] [2] European Medicines Agency. (n.d.). Good manufacturing practice (GMP). Retrieved from [EMA Website] [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1997). Impurities: Guideline for residual solvents Q3C(R6). [4] United States Pharmacopeial Convention. (2023). United States Pharmacopeia and National Formulary (USP-NF). [5] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP). Retrieved from [EDQM Website]